lundi 16 novembre 2026
RechercherExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each, so you can check any claim. How we source
Source document· October 26, 2026

LLY vs. MRK: Which Stock Offers the More Compelling Investment Case?

View original at finance.yahoo.com
LLY vs. MRK: Which Stock Offers the More Compelling Investment Case? Eli Lilly LLY and Merck MRK are leading global pharmaceutical companies with blockbuster drug portfolios and promising pipelines…
Opening lines of the source · short snapshot: read the full document at the original

Ce que nous avons tiré de cette source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Foundayo's launch uptake has been encouraging as Lilly expands physician engagement and direct-to-consumer promotion in the United States.

    60% confidence
  • Foundayo could be a commercial game-changer for Lilly, offering a more convenient alternative to once-weekly injectables like Zepbound and Wegovy.

    60% confidence
  • Retatrutide could potentially deliver greater weight loss and broader metabolic benefits than current therapies, creating another multibillion-dollar growth driver.

    60% confidence
  • Lilly plans to seek FDA approval for retatrutide in the first quarter of 2027.

    60% confidence
LLY vs. MRK: Which Stock Offers the More Compelling Investment Case?: Source | Via News | fr.via.news